Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 45Breast 3Other hematologic neoplasm 2Lymphoid 2Sarcoma 1

Conditions

Breast Neoplasms 3Neoplasm Metastasis 1

Interventions

Trastuzumab 728Paclitaxel 694Cyclophosphamide 647Docetaxel 559Capecitabine 485Letrozole 437Fulvestrant 398Carboplatin 397Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 272exemestane 258Epirubicin 251Radiotherapy 239pertuzumab 237palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 151Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Estramustine × Breast × Clear all
NCT02866955 2020-03-09

EFESE

Institut de Cancérologie de Lorraine

Phase 2 Completed
100 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02853071 2019-11-18

BEST

Centre Hospitalier Universitaire de Besancon

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT00003066 2014-01-06

Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
40 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡